A further 1.4 million people with an increased risk for progression to severe COVID-19 will be eligible for Paxlovid following a positive test.
NICE already recommends the antiviral for an estimated 3.9 million people who do not need supplemental oxygen for COVID-19 and for those who have an increased risk for progression to severe COVID-19.
This includes people with certain cancers, people who have had a haematological stem cell transplant or a haematological disease and people living with liver or kidney disease…
